Physician profile
Maci E Hobby
NPI 1083018667
$2,136.03
in general payments reported to CMS, 2019-2025
21 companies · $917 in 2025
The $917 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.44 · 2023: $375 · 2024: $797 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060 · Education: $28.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.26 |
| Education | $28.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $796.55 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Travere Therapeutics, INC. | $307.36 | 2024-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $109.26 | 2023-2025 | |
| Corcept Therapeutics | $81.21 | 2023-2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $76.29 | 2024-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $75.28 | 2023-2024 | Velphoro |
| Xeris Pharmaceuticals, INC. | $69.56 | 2024-2025 | Keveyis |
| Mallinckrodt Hospital Products INC. | $62.02 | 2021-2024 | Acthar |
| Amgen INC. | $59.30 | 2025 | Krystexxa |
| Ani Pharmaceuticals, INC. | $59.11 | 2023 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $58.41 | 2023-2025 | |
| Lilly USA, LLC | $54.16 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $53.55 | 2025 | Farxiga |
| Opko Pharmaceuticals, LLC | $52.00 | 2023-2025 | Rayaldee |
| Vifor Pharma, INC. | $49.10 | 2023 | Veltassa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $45.37 | 2023 | Omnipod |
| Calliditas Therapeutics US INC. | $41.90 | 2024-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $32.00 | 2021 | |
| Aurinia Pharma U.S., INC. | $23.88 | 2023 | Lupkynis |
| Paratek Pharmaceuticals, INC. | $15.19 | 2024 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.53 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maci Hobby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.